Sometimes it's good to just rally the troops a bit. While I didn't see anything especially new in Roche's (RHHBY.OB)
Investor Day presentations, it was a good reminder as to the depth,
breadth, and quality of this Big Pharma's drug and diagnostics pipeline.
History says that several of these currently-promising programs will
fall by the wayside, and Roche's shares are not quite slam-dunk cheap,
but this remains a quality to name to hold in the healthcare space.
Please read more here:
Roche Hosts An Encouraging Investor Day
No comments:
Post a Comment